Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

En studie av HLD-0915 hos pasienter med metastatisk kastrasjonsresistent prostatakreft (MCRPC)

2. november 2026 oppdatert av: Janssen Research & Development, LLC

Fase 1/2 studie av HLD-0915 hos pasienter med metastatisk kastrasjonsresistent prostatakreft (MCRPC)

Assessment of the safety and efficacy of HLD-0915 (JNJ-101556143) in patients with metastatic prostate cancer who have progressed on prior systemic therapies, with further evaluation in additional prostate cancer populations.

Studieoversikt

Studietype

Intervensjonell

Registrering (Antatt)

190

Fase

  • Fase 2
  • Fase 1

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studiesteder

    • Colorado
      • Colorado Springs, Colorado, Forente stater, 80909
        • Rekruttering
        • Rocky Mountain Cancer Center
      • Denver, Colorado, Forente stater, 80218
        • Rekruttering
        • Sarah Cannon Research Institute 1
    • Connecticut
      • New Haven, Connecticut, Forente stater, 06511
        • Rekruttering
        • Yale University
    • Florida
      • Sarasota, Florida, Forente stater, 34232
        • Rekruttering
        • Florida Cancer Specialists
    • Louisiana
      • Metairie, Louisiana, Forente stater, 70006
        • Rekruttering
        • XCancer Research Network LCMC Health EJGH
    • Massachusetts
      • Boston, Massachusetts, Forente stater, 02114
        • Rekruttering
        • Dana Farber Mass General Brigham Cancer Care Inc
    • Michigan
      • Grand Rapids, Michigan, Forente stater, 49546
        • Rekruttering
        • South Texas Accelerated Research Therapeutics, LLC (START)
    • Nebraska
      • Omaha, Nebraska, Forente stater, 68130
        • Rekruttering
        • Urology Cancer Center, PC
    • New York
      • Long Island City, New York, Forente stater, 11101
        • Rekruttering
        • Memorial Sloan Kettering Cancer Center
      • Syracuse, New York, Forente stater, 13210
        • Rekruttering
        • Associated Medical Professionals
    • North Carolina
      • Durham, North Carolina, Forente stater, 27710
        • Rekruttering
        • Duke University Medical Center
    • South Carolina
      • Myrtle Beach, South Carolina, Forente stater, 29572
        • Rekruttering
        • Carolina Urologic Research Center
    • Tennessee
      • Nashville, Tennessee, Forente stater, 37203
        • Rekruttering
        • Sarah Cannon Research Institute
      • Nashville, Tennessee, Forente stater, 37209
        • Rekruttering
        • Urology Associates
    • Texas
      • Austin, Texas, Forente stater, 78758
        • Rekruttering
        • NEXT Oncology
      • Houston, Texas, Forente stater, 77030
        • Rekruttering
        • MD Anderson Cancer Center
    • Virginia
      • Norfolk, Virginia, Forente stater, 23502
        • Rekruttering
        • Virginia Clinical Research
      • Sutton, Storbritannia, SM2 5PT
        • Rekruttering
        • The Royal Marsden NHS Trust

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Mann

Beskrivelse

Patients must meet the following criteria to be eligible study participation:

Key Inclusion Criteria:

All Study Arms (Phase 1 Part 1 & 2, Phase 2 Part 1, Part 2A, 2B, 2C & 2D):

Males ≥ 18 years old Histological, pathological, and/or cytological confirmation of prostate adenocarcinoma Adequate hematological, renal, and hepatic function. Able to swallow oral medication

mCRPC Arms: (Phase 1 Part 1 & 2, Phase 2 Part 1): Prior orchiectomy or ongoing androgen-deprivation therapy and a castrate level of serum testosterone Progressive mCRPC defined as having demonstrated PSA progression on the prior regimen

SOAR Arm (Phase 2 Part 2A) mHSPC with distant metastatic disease based on conventional imaging PSA ≥0.2 ng/mL, following treatment with next generation ARPI for at least 180 days and up to 365 days No evidence of radiographic or PSA progression while receiving ARPI

mHSPC arms (Phase 2 Part 2B, 2C & 2D) serum testosterone >150ng/ml mHSPC with distant metastatic disease based on conventional imaging and PSA >2.0 ng/mL

Key Exclusion Criteria:

All arms (Phase 1 Part 1 & 2, Phase 2 Part 1, Part 2A, 2B, 2C & 2D):

Has experienced a recent major bleed or has a known bleeding disorder Tumors exhibiting neuroendocrine or small cell carcinoma component by histopathology Receiving continuous corticosteroids at prednisone-equivalent dose of >10 mg/day Prior or ongoing significant medical condition

mCRPC arms: (Phase 1 Part 1 & 2, Phase 2 Part 1): Has received systemic anti-cancer therapy or investigational drugs within 2 weeks prior to first dose of study drug with certain exceptions requiring longer washout periods

SOAR arm (Phase 2 Part 2A) Has received any prior cytotoxic chemotherapy for prostate cancer

mHSPC arms (Phase 2 Part 2B, 2C & 2D) regional pelvic lymph node disease only

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Ikke-randomisert
  • Intervensjonsmodell: Sekvensiell tildeling
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: JNJ-101556143 Phase 1 Part 1 - Dose Escalation

Treatment cycle consists of 21 days. Treatment may continue until disease progression or study discontinuation (withdrawal of consent, intercurrent illness, unacceptable adverse event or any other changes unacceptable for further treatment, etc.)

Experimental: Oral JNJ-101556143

Eksperimentell: JNJ-101556143 Phase 1 Part 2 - Formulation Exploration

Treatment cycle consists of 21 days. Treatment may continue until disease progression or study discontinuation (withdrawal of consent, intercurrent illness, unacceptable adverse event or any other changes unacceptable for further treatment, etc.)

Experimental: Oral JNJ-101556143

Experimental: Oral JNJ-101556143

Experimental: Oral JNJ-101556143

Eksperimentell: JNJ-101556143 Phase 2 Part 1 - Dose Optimization

Treatment cycle consists of 21 days. Treatment may continue until disease progression or study discontinuation (withdrawal of consent, intercurrent illness, unacceptable adverse event or any other changes unacceptable for further treatment, etc.)

Experimental: Oral JNJ-101556143

Eksperimentell: Phase 2 Part 2A - SOAR

Treatment cycle consists of 21 days. Treatment may continue until disease progression or study discontinuation (withdrawal of consent, intercurrent illness, unacceptable adverse event or any other changes unacceptable for further treatment, etc.)

Experimental: Oral JNJ-101556143

Eksperimentell: Phase 2 Part 2B - HSPC Expansion

Treatment cycle consists of 21 days. Treatment may continue until disease progression or study discontinuation (withdrawal of consent, intercurrent illness, unacceptable adverse event or any other changes unacceptable for further treatment, etc.)

Experimental: Oral JNJ-101556143

Eksperimentell: Phase 2 Part 2C - HSPC Expansion

Treatment cycle consists of 21 days. Treatment may continue until disease progression or study discontinuation (withdrawal of consent, intercurrent illness, unacceptable adverse event or any other changes unacceptable for further treatment, etc.)

Experimental: Oral JNJ-101556143

Eksperimentell: Phase 2 Part 2D - HSPC Expansion

Treatment cycle consists of 21 days. Treatment may continue until disease progression or study discontinuation (withdrawal of consent, intercurrent illness, unacceptable adverse event or any other changes unacceptable for further treatment, etc.)

Experimental: Oral JNJ-101556143

Hva måler studien?

Primære resultatmål

Resultatmål
Tidsramme
Frequency of dose-limiting toxicities (DLTs)
Tidsramme: 21 days
21 days
Frequency and severity of AEs and abnormal ECG, laboratory and clinical changes since baseline
Tidsramme: 21 days
21 days
Phase 1 Part 2 (formulation exploration) relative bioavailability
Tidsramme: 22 days
22 days

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
PK Parameters
Tidsramme: 21 days
21 days
Duration of Response (DOR)
Tidsramme: 21 days
21 days
Radiographic Progression-Free Survival (rPFS)
Tidsramme: 63 days
63 days
Time to Response (TTR)
Tidsramme: 63 days
63 days
Change in PSA over time
Tidsramme: 21 days

Including PSA50 and PSA90 response

21 days
Objective Response Rate (ORR)
Tidsramme: 63 days

Per RECIST in evaluable patients

63 days

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Etterforskere

  • Studieleder: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

6. februar 2025

Primær fullføring (Antatt)

17. august 2028

Studiet fullført (Antatt)

17. august 2028

Datoer for studieregistrering

Først innsendt

20. januar 2025

Først innsendt som oppfylte QC-kriteriene

27. januar 2025

Først lagt ut (Faktiske)

30. januar 2025

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

3. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

2. november 2026

Sist bekreftet

1. november 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Ja

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere